ImageneBio, Inc. (NASDAQ:IMA) Given Average Recommendation of “Hold” by Analysts

ImageneBio, Inc. (NASDAQ:IMA) has been assigned a consensus rating of “Hold” from the five ratings firms that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, one has given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $30.00.

A number of analysts have recently weighed in on IMA shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImageneBio in a research report on Monday, June 29th. HC Wainwright began coverage on shares of ImageneBio in a research note on Friday. They set a “buy” rating on the stock. Wedbush reaffirmed an “underperform” rating on shares of ImageneBio in a research note on Monday, May 11th. Finally, Wall Street Zen lowered shares of ImageneBio from a “sell” rating to a “strong sell” rating in a report on Sunday, May 17th.

Institutional Investors Weigh In On ImageneBio

Institutional investors have recently modified their holdings of the stock. Blue Owl Capital Holdings LP purchased a new position in shares of ImageneBio in the 2nd quarter worth about $5,414,000. Deep Track Capital LP bought a new position in shares of ImageneBio in the third quarter worth approximately $7,160,000. Cable Car Capital LP purchased a new stake in shares of ImageneBio during the second quarter valued at approximately $4,611,000. Trails Edge Capital Partners LP bought a new stake in shares of ImageneBio during the second quarter valued at approximately $1,663,824,000. Finally, Vanguard Group Inc. purchased a new position in ImageneBio in the 3rd quarter worth approximately $1,902,000. 75.00% of the stock is owned by hedge funds and other institutional investors.

ImageneBio Price Performance

NASDAQ IMA opened at $5.61 on Friday. ImageneBio has a 1 year low of $3.94 and a 1 year high of $14.34. The stock has a market capitalization of $63.67 million, a PE ratio of -1.22 and a beta of 0.76. The business’s 50-day moving average is $5.79 and its 200 day moving average is $5.87.

ImageneBio (NASDAQ:IMA) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.27. As a group, equities research analysts anticipate that ImageneBio will post -3.07 earnings per share for the current year.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.